3 documents found, page 1 of 1
TERT promoter mutation as a potential predictive biomarker in BCG-treated bladd...
Batista, R; Lima, L; Vinagre, J; Pinto, V; Lyra, J; Máximo, V; Santos, L; Soares, PTelomerase reverse transcriptase gene promoter (TERTp) mutations are recognized as one of the most frequent genetic events in bladder cancer (BC). No studies have focused on the relevance of TERTp mutations in the specific group of tumors treated with Bacillus Calmette–Guérin (BCG) intravesical therapy. Methods — 125 non muscle invasive BC treated with BCG therapy (BCG-NMIBC) were screened for TERTp mutations, ...
Medical Termination of Delayed Miscarriage: Four-Year Experience with an Outpat...
Lyra, J; Cavaco-Gomes, J; Moucho, M; Montenegro, NPurpose: To evaluate the efficacy of an outpatient protocol with vaginal misoprostol to treat delayed miscarriage. Methods: Retrospective analysis of prospectively collected data on women medically treated for missed abortion with an outpatient protocol. The inclusion criteria were: ultrasound-based diagnosis of missed abortion with less than 10 weeks; no heavy bleeding, infection, inflammatory bowel disease or...
Frequency of TERT promoter mutations in human cancers
Vinagre, J; Almeida, A; Pópulo, H; Batista, R; Lyra, J; Pinto, V; Coelho, R; Celestino, R; Prazeres, H; Lima, L; Melo, M; Rocha, AG; Preto, A; Castro, PReactivation of telomerase has been implicated in human tumorigenesis, but the underlying mechanisms remain poorly understood. Here we report the presence of recurrent somatic mutations in the TERT promoter in cancers of the central nervous system (43%), bladder (59%), thyroid (follicular cell-derived, 10%) and skin (melanoma, 29%). In thyroid cancers, the presence of TERT promoter mutations (when occurring tog...